<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cytosorbents Crp — News on 6ix</title>
<link>https://6ix.com/company/cytosorbents-crp</link>
<description>Latest news and press releases for Cytosorbents Crp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cytosorbents-crp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355aa578dffbe2df0eb90f.webp</url>
<title>Cytosorbents Crp</title>
<link>https://6ix.com/company/cytosorbents-crp</link>
</image>
<item>
<title>CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross marginsEnhanced Balance Sheet Flexibility with an Additional $2.5 million</description>
</item>
<item>
<title>CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-announces-hotswaptm-launch-renewed-aferetica-partnership-and-new-clinical-evidence-at-isicem-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-announces-hotswaptm-launch-renewed-aferetica-partnership-and-new-clinical-evidence-at-isicem-2026</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the</description>
</item>
<item>
<title>CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-6</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the</description>
</item>
<item>
<title>CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-preliminary-unaudited-fourth-120000583</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-preliminary-unaudited-fourth-120000583</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced preliminary unaudited fourth quarter and full-year 2025 financial results and business update.</description>
</item>
<item>
<title>CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-participate-virtual-fireside-chat-120000511</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-participate-virtual-fireside-chat-120000511</guid>
<pubDate>Wed, 10 Dec 2025 12:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company's recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance she</description>
</item>
<item>
<title>Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/cytosorbents-crp/news/updated-cytosorbents-present-jefferies-global-224200510</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/updated-cytosorbents-present-jefferies-global-224200510</guid>
<pubDate>Mon, 17 Nov 2025 22:42:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom.</description>
</item>
<item>
<title>CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-third-quarter-2025-210500050</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-third-quarter-2025-210500050</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2025, and recent business highlights.</description>
</item>
<item>
<title>CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-participate-jefferies-global-healthcare-120000683</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-participate-jefferies-global-healthcare-120000683</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.</description>
</item>
<item>
<title>CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-report-third-quarter-2025-110000731</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-report-third-quarter-2025-110000731</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025.</description>
</item>
<item>
<title>In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer</title>
<link>https://6ix.com/company/cytosorbents-crp/news/memoriam-dr-robert-hawes-bartlett-110000452</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/memoriam-dr-robert-hawes-bartlett-110000452</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, honors the life and legacy of Dr. Robert Hawes Bartlett, MD (1939-2025), the company's former Chief Medical Officer from 2008-2017, who passed away last week at age 86.</description>
</item>
<item>
<title>CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-showcase-pioneering-cardiac-surgery-110000913</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-showcase-pioneering-cardiac-surgery-110000913</guid>
<pubDate>Mon, 29 Sep 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, the world's largest gathering for the global cardiothoracic community, taking place October 8–11, 2025 in Copenhagen, Denmark. The meeting is expected to attract more than 5,000 attendees from</description>
</item>
<item>
<title>CytoSorbents Provides DrugSorb-ATR Regulatory Update</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-provides-drugsorb-atr-regulatory-110000969</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-provides-drugsorb-atr-regulatory-110000969</guid>
<pubDate>Tue, 16 Sep 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorb™-ATR.</description>
</item>
<item>
<title>CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-host-global-webinar-turning-110000193</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-host-global-webinar-turning-110000193</guid>
<pubDate>Mon, 08 Sep 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, details its upcoming World Sepsis Day Global Webinar, entitled, "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" to be held on Wednesday, September 10, 2025, in commemoration of Sepsis Awareness Month and World Sepsis Day.</description>
</item>
<item>
<title>CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-present-h-c-wainwright-110000595</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-present-h-c-wainwright-110000595</guid>
<pubDate>Fri, 05 Sep 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the H.C. Wainwright 27th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York, NY on September 8, 2025.</description>
</item>
<item>
<title>CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-updates-u-fda-regulatory-110000261</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-updates-u-fda-regulatory-110000261</guid>
<pubDate>Wed, 20 Aug 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, updates the regulatory status of its appeal with the U.S. Food and Drug Administration (FDA) for De Novo market authorization of DrugSorb™-ATR.</description>
</item>
<item>
<title>CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the</description>
</item>
<item>
<title>CytoSorbents Leads a New Era in Sepsis Treatment</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-leads-era-sepsis-treatment-110000568</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-leads-era-sepsis-treatment-110000568</guid>
<pubDate>Thu, 31 Jul 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights new studies that demonstrate the vital and evolving role of CytoSorb® therapy in the treatment of sepsis and septic shock – among the deadliest challenges in critical care medicine. Recent data demonstrate early and intensive use of CytoSorb therapy improves clinical outcomes for patients suffering from these conditi</description>
</item>
<item>
<title>CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-report-second-quarter-2025-110000234</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-report-second-quarter-2025-110000234</guid>
<pubDate>Tue, 29 Jul 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2025 financial results and recent business highlights after the market close on Thursday, August 7, 2025.</description>
</item>
<item>
<title>CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-provides-u-fda-health-110000221</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-provides-u-fda-health-110000221</guid>
<pubDate>Wed, 02 Jul 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada. DrugSorb-ATR is an FDA-designated Breakthrough Device designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of st</description>
</item>
<item>
<title>CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR</title>
<link>https://6ix.com/company/cytosorbents-crp/news/cytosorbents-files-appeal-u-fda-110000992</link>
<guid isPermaLink="true">https://6ix.com/company/cytosorbents-crp/news/cytosorbents-files-appeal-u-fda-110000992</guid>
<pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
<description>CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, (the denial letter). DrugSorb-ATR, which previously received B</description>
</item>
</channel>
</rss>